Aurinia Pharmaceuticals shares surge on Gilead acquisition rumors By Investing.com

Shares of Aurinia Pharmaceuticals (NASDAQ: NASDAQ:) saw a notable increase today, rising by 6.7% amid speculation about a potential acquisition by Gilead Sciences (NASDAQ:). The rumors were sparked by the sighting of a Gilead jet at the Edmonton headquarters of Aurinia, suggesting that discussions might be underway. This comes after Aurinia’s announcement in June about exploring strategic alternatives.

Investors and analysts are closely watching the situation, with RBC Capital Markets weighing in on the possible sale price. This potential buyout has been a subject of interest since October 2021, when Bristol-Myers Squibb (NYSE:)’s prior interest in Aurinia came to light, fueling ongoing speculation within the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.